Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Highlights this week included:

CAFC: Patentability of isolated genes Association for Molecular Pathology v USPTO and Myriad Genetics – Myriad files brief (Patently-O) (Holman’s Biotech IP Blog) (Holman’s Biotech IP Blog)

Glivec (Imatinib) – Brazil: Supreme Court of Justice denies extension of Glivec patent (IP tango)

Plavix (Clopidogrel) – US: $442 million fine against Apotex for Plavix patent infringement (GenericsWeb) (Philip Brooks’ Patent Infringement Updates) (Corante)

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

General

GSK forms alliance for development of gene therapy techniques for rare diseases (Patent Docs)

Emerging economies’ new initiative on falsified and substandard medicines (IP Watch)

Michèle Rivasi asks question about ACTA and Access to Medicine (KEI)

As negotiators launch talks on biodiversity, industry requests IP protection (IP Watch)

Negotiators persist on biodiversity benefit-sharing treaty despite slipping deadlines (IP Watch)

New draft biodiversity treaty text shows much work remains; Co-chairs hopeful (IP Watch)

Biodiversity negotiators move treaty text forward; Deadline pushed to Monday (IP Watch)

NGOs: Biopiracy ongoing as Governments slowly negotiate international instrument (IP Watch)

Study touts economic benefits of biodiversity (IP Watch)

Stakeholders restless about biodiversity benefit sharing protocol (IP Watch)

Climate-ready crop patents present danger for biodiversity, group says (IP Watch)

Draft report of Plant Variety Protection Council now available (IP Watch)

Bringing better medicines to market faster, an interview with expert John Avellanet (BiotechBlog)

Canada: Indigenous groups allege Canadian obstructionism to biodiversity ABS protocol (IP Watch)

Canada/EU draft agreement on data protection on plant protection products and rules on avoidance of duplicative testing (KEI)

China: Rules on genetic resources tightened (China Blawg)

EU: Yeda application heads for ECJ on indirect/contributory infringement issue: Yeda Research and Development Company and Aventis Holdings v Comptroller General of Patents (The SPC Blog)

India: Minister: India anticipates European fix to law delaying generics shipments (IP Watch)

Japan: Delegates see UN protocol against biopiracy within reach (IP Watch) (IP Watch)

Lithuania: Lithuanian Kirin Amgen ECJ reference: a local lawyer comments (The SPC Blog)

US: FDA considers tighter standards for generics (GenericsWeb)

USPTO Peer to Patent Program expanded to include biotech patent applications (Patent Docs)

USPTO requesting comments on humanitarian technologies (PatentlyBIOtech)

US: CAFC: Patentability of isolated genes Association for Molecular Pathology v USPTO and Myriad Genetics – Myriad files brief (Patently-O) (Holman’s Biotech IP Blog) (Holman’s Biotech IP Blog)

US: Bayer submits brief in Therasense v Becton Dickinson (Patent Docs)

US: Ryogen awarded two additional patents for human genes (BiotechBlog)

US: District Court Nebraska: Streck patents valid, infringed by Research and Diagnostics System (BiotechBlog)

Products

Allegra-D (Fexofenadine, Pseudoephedrine) – US: Wockhardt receives US FDA approval for generic version of Allegra-D 12 hour (GenericsWeb)

Differin (Adapalene) – US: Galderma files patent infringement complaint against Actavis following Para IV certification (Patent Docs)

Dilaudid (Hydromorphone hydrochloride) – US: Purdue files patent infringement complaint against Hospira following Para IV certification (Patent Docs)

Elestat (Epinastine hydrochloride ophthalmic solution) – US: Sandoz seeks declaratory judgment of invalidity and non infringement based on ANDA filing and continued Orange Book listing: Sandoz v Boehringer Ingelheim (Patent Docs)

Femcon, Loestrin (Norethindrone, Ethinyl estradiol, Ferrous fumarate) – US: Warner Chilcott settles Loestrin, Femcon patent suit with Lupin (Patent Docs)

Femcon Fe (Norethindrone, Ethinyl estradiol, Ferrous fumarate) – US: Warner Chilcott files patent infringement complaint against Mylan following Para IV certification (Patent Docs)

Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement complaint against Accord Healthcare following Para IV certification (Patent Docs)

Glivec (Imatinib) – Brazil: Supreme Court of Justice denies extension of Glivec patent (IP tango)

Hectorol (Doxercalciferol) – US: FDA grants petition requesting a ‘superseding’ 30-month stay for generic Hectorol (FDA Law Blog)

Humira (Adalimumab) – Netherlands: District Court of The Hague invalidates Dutch part of Bayer’s patent due to insufficiency: Bayer Healthcare v. Abbott (EPLAW)

Lunesta (Eszopiclone) – US: Cobalt Pharmaceuticals and Sepracor settle Lunesta patent litigation (Patent Docs)

Mirapex (Pramipexole) – US: Mylan receives approval for generic version of Mirapex tablets (SmartBrief)

Oracea (Doxycyline) – US: Mylan seeks declaratory judgment of non-infringement and invalidity based on ANDA filing: Mylan v Galderma (Patent Docs)

Perlane, Restylane (Hyaluronic acid) – US: Genzyme files patent infringement complaint against Medicis over manufacture, sale of Restylane and Perlane products (Patent Docs)

Plavix (Clopidogrel) – US: $442 million fine against Apotex for Plavix patent infringement (GenericsWeb) (Philip Brooks’ Patent Infringement Updates) (Corante)

Prandin (Repaglinide) – US: Novo fails to dismiss suit over validity of Prandin patent (Patent Docs)

Revlimide (Linalidomide) – US: Celegen files patent infringement complaint against Natco following Para IV certification (Patent Docs)